Pemigatinib in Treating Patients With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Rearrangement

NCT04256980 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

34

Enrollment

INDUSTRY

Sponsor class

Conditions

Cholangiocarcinoma

Interventions

DRUG: Pemigatinib

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.